ATHA Athira Pharma

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma to Participate in Upcoming May Conferences

BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.

Sidoti May 2024 Virtual Investor Conference

Format: Company Presentation

Date and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET

Location: Virtual

The Citizens JMP Life Sciences Conference

Format: Fireside Chat

Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET

Location: New York Hilton Midtown

Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit . You can also follow Athira on ,  and @athirapharma on , (formerly known as ), and .

Investor Contacts:

Julie Rathbun

Athira Pharma



206-769-9219

Anne Marie Fields

Stern Investor Relations



332-213-1956

Media Contact:

Janine Bogris

Inizio Evoke Comms



201-245-6838



EN
02/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Athira Pharma

 PRESS RELEASE

Athira Pharma Announces Proposed Settlement of Stockholder Derivative ...

Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that the U.S. District Court for the Western District of Washington issued an order providing for preliminary approval of a proposed settlement of the claims asserted nominally on behalf of Athira against the individual defendants named in the previously disclosed stockholder derivative actions...

 PRESS RELEASE

Athira Pharma Reports First Quarter 2024 Financial Results and Pipelin...

Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates Topline data from Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease expected in second half of 2024  Submitted Investigational New Drug application to U.S. Food and Drug Administration for ATH-1105 for the treatment of amyotrophic lateral sclerosis; On track to dose subjects in a first-in-human study in second quarter of 2024 Strong balance sheet to support innovative pipeline through key clinical inflection points BOTHELL, Wash., M...

 PRESS RELEASE

Athira Pharma to Participate in Upcoming May Conferences

Athira Pharma to Participate in Upcoming May Conferences BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual The Citizens JMP Life Sciences ConferenceFormat: Fireside...

 PRESS RELEASE

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Offic...

Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization BOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and...

 PRESS RELEASE

Athira Pharma Announces Publication of Preclinical Data Highlighting F...

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease BOTHELL, Wash., April 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch